Construction method and application of CXCL16 gene humanized animal model

The CXCL16 gene was replaced in a mouse model through CRISPR/Cas9 technology to construct a humanized mouse model, which solved the problem that the existing model could not simulate human CXCL16 signal transduction, achieved more accurate drug evaluation and research, and enhanced Preclinical guidance of drug development.

CN118910165APending Publication Date: 2024-11-08SHANGHAI BIOMODEL ORGANISM SCI & TECH DEV

Patent Information

Application Number
CN202411412977.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Due to the differences in amino acid sequences of human mouse proteins, existing mouse models cannot effectively simulate human CXCL16 signaling and disease models, limiting the efficacy and pharmacological and toxicological research of human CXCL16 target drugs.

Method used

Through CRISPR/Cas9 gene editing technology, the mouse CXCL16 gene was replaced with the human CXCL16 gene, and a mouse model with human CXCL16 target was constructed to ensure that the model could interact with human CXCL16 antibodies and express human CXCL16 protein.

Benefits of technology

The construction of a humanized mouse model was realized, and the efficacy evaluation and toxicological research of human CXCL16 target drugs were enhanced, providing an experimental model closer to human biological behavior, reducing preclinical and clinical experimental results. The difference.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910165A_ABST
    Figure CN118910165A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and relates to a construction method and application of a humanized gene modified animal model, in particular to a construction method and application of a CXCL16 gene humanized animal model. The invention provides a CXCL16 gene humanized animal cell and an animal model construction method and application, and the CXCL16 gene humanized animal model constructed by the invention can accelerate the research progress in the fields related to human CXCL16 gene or protein, for example, the CXCL16 gene humanized animal model can be used for evaluating the drug effect of a human CXCL16 target drug. The method has important guiding significance on clinical effects of drug development, is an ideal model for drug safety evaluation, and is used for carrying out clinical in-vivo evaluation on toxicology of human CXCL16 target drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and relates to a method for constructing and applying a humanized gene-modified animal model, and specifically relates to a method for constructing and applying a CXCL16 gene humanized animal model. Background Art

[0002] Tumors contain not only cancer cells, but also cells that support tumor growth and immune cells that suppress tumors. Early studies have shown that chemokines play an important role in the function of immune system cells. However, as time goes by, more and more studies have shown that chemokines play an important role in the occurrence and development of cancer. Chemokines are an important class of cytokines that are mainly responsible for regulating the directional migration of immune cells, namely chemotaxis. In the occurrence and development of tumors, chemokines play multiple roles and are closely linked to a variety of cancer-related biological processes.

[0003] CXC-domain chemokine ligand 16 (CXCL16) belongs to the α-chemokine subfamily and can regulate the proliferation, migration, invasion and responsiveness of tumor cells to treatment. It plays a complex and important role in the occurrence and development of tumors. Studies have shown that CXCL16 can not only be produced and secreted by tumor cells, but also be expressed by other cells in the tumor microenvironment, participating in the regulation of inflammatory response, immune cell recruitment and tumor-related angiogenesis. In addition, CXCL16 also has the function of mediating signal transduction. By interacting with the CXCR6 receptor, it activates multiple signaling pathways, including PI3K / Akt, ERK / MAPK and calcium ion signaling pathways, thereby further affecting the biological behavior of tumor cells. Existing evidence shows that soluble CXCL16 can increase the proliferation of tumor cells such as colon cancer, gastric cancer, and glioma, and participate in the pathogenesis of diseases such as non-small cell lung cancer and triple-negative breast cancer. Therefore, CXCL16 has also become one of the hot targets for tumor immunotherapy. Currently, an antibody drug called CLS-A-101 targeting the CXCL16 target has entered the preclinical research stage. The drug will be mainly used for the treatment and research of breast cancer.

[0004] In preclinical drug research, mice are widely used in drug efficacy evaluation, pharmacology and toxicology analysis, etc. The premise for these studies is that drugs acting on human targets can bind to or activate the corresponding targets of mice. If the test drug cannot bind to the mouse target or activate the downstream signaling pathway, mice cannot be used for drug efficacy, pharmacology and toxicology evaluation. By comparing the CXCL16 protein of humans and mice, it was found that the amino acid consistency of the CXCL16 protein of humans and mice was only 46%. This difference in the amino acid sequence of human and mouse proteins is likely to cause drugs targeting human CXCL16 targets to be unable to recognize mouse CXCL16 targets, especially antibody drugs. A difference in the recognition site of one amino acid may cause the antibody to be unable to recognize the target site. Therefore, it is likely that wild-type mice cannot be used to simulate signal transduction, disease model establishment, drug evaluation and screening studies targeting human CXCL16. Animal model experiments are an essential part of preclinical drug research, and the lack of models may become a bottleneck in drug development. The current lack of small animal models of human CXCL16 limits research on human CXCL16 signal transduction, disease research, drug screening and evaluation.

[0005] With the continuous development and maturity of genetic engineering technology, the use of human cells or genes to replace or displace endogenous similar cells or genes of animals to establish a biological system or disease model closer to humans and establish a humanized experimental animal model (humanized animal model), which has provided an important tool for new clinical treatment methods or means. Among them, the genetic humanized animal model, that is, using gene modification operation technology to replace animal homologous genes with normal or mutant human genes, can establish a genetic humanized animal model of normal or mutant genes that are closer to human disease characteristics in animals. Genetically humanized animals not only have important application value in themselves, such as gene humanization can improve the recognition of drugs to drug targets in the body, but more importantly, due to the presence of human gene fragments, proteins with human functions can be expressed or partially expressed in animals, thereby greatly reducing the difference between preclinical animal experiments and clinical experimental results, and providing the possibility of drug screening and verification at the level of preclinical animals. Summary of the invention

[0006] The purpose of the present invention is to construct a humanized mouse model with a human CXCL16 target, which has a very high application value in screening and evaluating human CXCL16 target drugs.

[0007] In order to achieve the above-mentioned purpose, the first aspect of the present invention discloses a human CXCL16 gene homologous recombination vector, which utilizes gene editing technology to replace the nucleotide sequence shown in SEQ ID NO: 3 in the animal CXCL16 gene with a homologous recombination vector to a human CXCL16 gene fragment; the human CXCL16 gene homologous recombination vector comprises a 5' homologous arm, a human CXCL16 gene fragment and a 3' homologous arm arranged in sequence from the 5' end to the 3' end; Wherein, the human CXCL16 gene fragment is selected from at least one of the following groups: 1) a replacement region of the human CXCL16 gene having a nucleotide sequence as shown in SEQ ID NO: 1; 2) a replacement region of the human CXCL16 gene having a nucleotide sequence as shown in SEQ ID NO: 9; 3) A nucleotide fragment encoding the amino acid sequence shown in SEQ ID NO: 2.

[0008] The nucleotide sequence of the 5' homology arm is shown in SEQ ID NO: 7; The nucleotide sequence of the 3' homology arm is shown in SEQ ID NO: 8; Wherein, gene editing is achieved using sgRNA, the sequence of the 5' target site targeted by the sgRNA is shown as SEQ ID NO: 19, and the sequence of the 3' target site targeted by the sgRNA is shown as SEQ ID NO: 20.

[0009] The construction method of the CXCL16 gene humanized animal model is as follows: The method comprises injecting a mixture of the above-mentioned human CXCL16 gene homologous recombination vector, sgRNA and Cas9 into the non-human animal cells, transferring the non-human animal cells into a culture medium for culture, and then screening to obtain CXCL16 gene humanized animal cells; in the CXCL16 gene humanized animal cells, reducing or eliminating the expression of the endogenous CXCL16 gene in the non-human animal cells, and expressing and producing the humanized CXCL16 protein.

[0010] S1: transplanting the above-mentioned CXCL16 gene humanized animal cells, or embryos developed from the CXCL16 gene humanized animal cells, into a surrogate mother for development to obtain F0 generation animals; S2: Selecting animals with positive genotype identification as F0 positive animals; then hybridizing and self-pollinating the F0 positive animals, and self-pollinating the heterozygous animals to obtain homozygous animals, thereby establishing stable humanized CXCL16 gene-modified animals; S3: The humanized CXCL16 gene-modified animal described in S2 is subjected to detection of humanized CXCL16 expression in tissues. If humanized CXCL16 is expressed, the humanized CXCL16 gene-modified animal is used as a CXCL16 gene humanized animal model.

[0011] Wherein, the Cas9 includes Cas9 mRNA and / or Cas9 protein.

[0012] Preferably, the non-human animal is a rodent, preferably a mouse, and the non-human animal cell is a fertilized egg cell; The fifth aspect of the present invention discloses the use of the above homologous recombination vector, CXCL16 gene humanized animal cell, CXCL16 gene humanized animal model in the field related to human CXCL16 gene or protein. It also includes the use of cells, cell lines or cell cultures, tissues, and organs derived from the CXCL16 gene humanized animal model in the field related to human CXCL16 gene or protein.

[0013] The application includes at least one of human CXCL16 gene function research, human CXCL16 antibody research, and drug construction and efficacy research targeting human CXCL16 target sites.

[0014] The CXCL16 gene humanized animal model can also be used as an animal experimental disease model for etiology research.

[0015] Compared with the prior art, the present invention has the following advantages: The present invention provides a method for constructing a CXCL16 gene humanized animal cell and an animal model and applications. The CXCL16 gene humanized animal model constructed by the present invention can accelerate research progress in fields related to the human CXCL16 gene or protein, for example, can be used to evaluate the efficacy of human CXCL16 target drugs, has important guiding significance for the clinical effect of drug development, and is also an ideal model for drug safety evaluation, and performs preclinical in vivo evaluation of the toxicology of human CXCL16 target drugs.

[0016] The present invention uses CRISPR / Cas9 gene editing technology to replace the mouse Cxcl16 gene with the human CXCL16 gene in mice with a healthy immune system, and constructs a mouse model that can interact with anti-human CXCL16 antibodies. Compared with ordinary mice, this model achieves humanization of key target molecules and retains a complete immune system. It can be used to screen and evaluate drugs targeting the human CXCL16 gene, and is an ideal preclinical drug testing model. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1Schematic diagram of the structure of mouse Cxcl16 gene and human CXCL16 gene.

[0018] Figure 2 Schematic diagram of the gene structure of CXCL16 in humanized mice after modification.

[0019] Figure 3 Schematic diagram of the recombination strategy for humanizing the mouse Cxcl16 gene.

[0020] Figure 4 This is the electrophoresis diagram of homologous recombination PCR identification results of F0 and F1 generation mice. Figure 4 A in the middle is the electrophoresis diagram of homologous recombination identification of 5' homology arm in F0 generation mice; Figure 4 Middle B is the electrophoresis diagram of homologous recombination identification of the 3' homology arm of the F0 generation; Figure 4 C and D are electrophoresis images of homologous recombination identification of 5' homology arm and 3' homology arm of F1 mice, respectively. The numbers above are the mouse numbers; M is a 1kb DNA marker.

[0021] Figure 5 Schematic diagram for qPCR primer position design.

[0022] Figure 6 The qPCR results of F2 wild-type mice and homozygous mice. HO is hCXCL16 homozygous mouse; WT is wild-type mouse; M is electrophoresis DNA marker.

[0023] Figure 7 The results of human CXCL16 protein expression in the serum of wild-type mice and homozygous mice. HO is hCXCL16 homozygous mouse; WT is wild-type mouse. DETAILED DESCRIPTION

[0024] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0025] The mouse strains, biochemical reagents, and experimental instruments used in the examples of the present invention are: The primer synthesis and sequencing services were purchased from Sangon Biotech (Shanghai) Co., Ltd.

[0026] C57BL / 6 and ICR mice were purchased from Shanghai Lingchang Biotechnology Co., Ltd.

[0027] EcoRI restriction endonuclease was purchased from NEB with the catalog number R3101M.

[0028] In-Fusion HD Cloning Kits were purchased from Takara, item number 639650.

[0029] The sgRNA in vitro transcription kit was purchased from Ambion, catalog number AM1354.

[0030] Escherichia coli DH5α competent cells were purchased from TaKaRa Company with catalog number 9057.

[0031] Cas9 mRNA comes from SIGMA, product number CAS9MRNA-1EA.

[0032] Human CXCL16 ELISA Kit was purchased from Abcam with the catalog number ab187397.

[0033] T7 Endonuclease I Detection Kit was purchased from NEB with the catalog number M0302S.

[0034] The PCR product gel recovery kit was QIAquick Gel Extraction Kit, purchased from QIAGEN, catalog number 28706.

[0035] Example 1 Construction of CXCL16 humanized mouse model 1) Humanization strategy design The human CXCL16 gene contains multiple transcripts, and the sequence design in this embodiment is mainly described by taking one of the transcripts as an example. The overall strategy of humanization is: from the DNA level, the coding region and intron region structure of the human CXCL16 gene (ENSEMBL Gene ID: ENSG00000161921) transcript (ENSEMBL ID: ENST00000574412.6) are replaced with the coding region and intron region of the corresponding mouse Cxcl16 gene (ENSEMBL Gene ID: ENSMUSG00000018920) transcript (ENSMUST00000019064.9).

[0036] The DNA sequence of the genomic replacement region of the human CXCL16 gene (ENSEMBL Gene ID: ENSG00000161921) transcript (ENSEMBL ID: ENST00000574412.6) is shown in SEQ ID NO: 1, and the corresponding protein amino acid sequence is shown in SEQ ID NO: 2. The DNA sequence of the genomic replacement region of the mouse Cxcl16 gene (ENSEMBL Gene ID: ENSMUSG00000018920) transcript (ENSMUST00000019064.9) is shown in SEQ ID NO: 3, and the corresponding protein amino acid sequence is shown in SEQ ID NO: 4.

[0037] Schematic diagram of the comparison between mouse Cxcl16 gene and human CXCL16 gene is shown in Figure 1 The schematic diagram of the final modified humanized mouse CXCL16 gene is shown in Figure 2 .

[0038] 2) gRNA target site screening In the process of constructing a gene-modified mouse model using CRISPR / Cas9, the gRNA target sequence determines its targeting specificity and the efficiency of inducing Cas9 to cut the target gene. The higher the efficiency of Cas9 cutting the target gene, the higher the efficiency of homologous recombination. Therefore, efficient and specific target sequence selection and design are the prerequisites for efficiently obtaining a gene-modified mouse model.

[0039] According to the sequence design, the present invention designs sgRNA. 1. Select 50 bp upstream and downstream of the replacement site as the gRNA target sequence. In the gRNA design website, select the gRNA with MITSpecificity Score>50 as the candidate gRNA; 2. After the gRNA shears the genome, the PAM region of the gRNA needs to be mutated to prevent secondary shearing. Therefore, the gRNA whose PAM region is located in the gene coding region is not preferred; 3. After the PAM region of gRNA is mutated, in theory, it should not affect or have the smallest possible impact on gene regulation, transcription, translation and other functions.

[0040] Following the above principles, ten sgRNAs were designed at the 5' target sequence and the 3' target sequence, respectively. The specific sequences are as follows: Table 1 5' end sgRNA design Serial number Sequence information 1 CTGCGGAGCTTGTTGGGACGAGG (SEQ ID NO: 21) 2 CGGCTTCTGCGGAGCTTGTTGGG (SEQ ID NO: 22) 3 CCGGCTTCTGCGGAGCTTGTTGG (SEQ ID NO: 23) 4 CTCCGCAGAAGCCGGAGATGAGG (SEQ ID NO: 24) 5 CCAACAAGCTCCGCAGAAGCCGG (SEQ ID NO: 25) 6 CGCCTCATCTCCGGCTTCTGCGG (SEQ ID NO: 19) 7 CAGAAGCCGGAGATGAGGCGGGG (SEQ ID NO: 26) 8 CCAAAGCCCCGCCTCATCTCCGG (SEQ ID NO: 27) 9 CCGGAGATGAGGCGGGGCTTTGG (SEQ ID NO: 28) 10 CGCAGAAGCCGGAGATGAGGCGG (SEQ ID NO: 29)

[0041] After analysis, the sgRNAs represented by numbers 2, 3, 8, and 9 in Table 1 were less efficient in gene editing and were therefore abandoned.

[0042] The PAM regions of the sgRNAs represented by numbers 4, 7, and 10 are all located in the gene coding region. Secondary splicing requires mutation of the PAM. These positions will introduce additional mutations in the human gene coding region, requiring additional modification of the human gene, and therefore they were abandoned.

[0043] The sgRNA represented by sequence number 1 is not recommended for use because its PAM region is far away from the cleavage site and its cutting efficiency is relatively low.

[0044] The sgRNA represented by No. 5 is not recommended for use because the mutation site is close to the transcription start site and will affect the transcription start.

[0045] The sgRNA represented by sequence number 6 has a lower risk of affecting shearing after mutation of the PAM region to prevent secondary shearing. Therefore, this gRNA is preferred as the 5' end gRNA for subsequent construction.

[0046] Table 2 3' end sgRNA Serial number Sequence information 1 CGCTAGGGTCTTGGTTCAACAGG (SEQ ID NO: 30) 2 CACTCTTGCTGTAGGCGCTA GGG (SEQ ID NO: 31) 3 CCTAGCGCCTACAGCAAGAGTGG (SEQ ID NO: 32) 4 CCACTCTTGCTGTAGGCGCTAGG (SEQ ID NO: 33) 5 TGCTGTAGGCGCTAGGGTCTTGG (SEQ ID NO: 34) 6 GTGTACCAGAGCTGCAAACCTGG (SEQ ID NO: 35) 7 TGAGCTTCCACTCTTGCTGTAGG (SEQ ID NO: 20) 8 CCAGAGCTGCAAACCTGGAAAGG (SEQ ID NO: 36) 9 CCTTTCCAGGTTTGCAGCTCTGG (SEQ ID NO: 37) 10 TGAGAGATGGATGATGACATGGG (SEQ ID NO: 38)

[0047] After analysis, the PAM regions of the sgRNAs represented by serial numbers 1, 2, 4, 5, 6, 8, and 9 in Table 2 are all located in the gene coding region. Secondary splicing requires mutation of the PAM. These positions will introduce additional mutations in the human gene coding region, requiring additional modification of the human gene, and therefore they were abandoned.

[0048] The sgRNA represented by sequence number 3 is not recommended for use because its PAM region is far from the cleavage site and its cleavage efficiency is relatively low.

[0049] The PAM region of the sgRNA represented by sequence number 7 is relatively close to the cleavage site, the cleavage efficiency should be high, and the risk of affecting gene regulation or expression after secondary cleavage to prevent mutations in the PAM region is low. Therefore, this gRNA is selected as the preferred 3' gRNA for subsequent construction.

[0050] 3) Construction of homologous recombination vector According to the sequence design, the present invention further designs the following Figure 3The homologous recombination scheme shown and the vector containing the 5' homology arm, the DNA fragment containing the human CXCL16 genome, and the 3' homology arm. The 5' homology arm (SEQ ID NO: 7) is the nucleotides 70350274-70353274 of the NCBI accession number NC_000077.7; the 3' homology arm (SEQ ID NO: 8) is the nucleotides 70343274-70346229 of the NCBI accession number NC_000077.7; the gene fragment sequence containing human CXCL16 after gene modification is shown in SEQ ID NO: 9. According to the design scheme, the mRNA sequence of human CXCL16 expressed by the transformed humanized mouse is shown in SEQ ID NO: 10, and the protein sequence is shown in SEQ ID NO: 2. According to the strategic design scheme, the CRISPR / Cas9 method is used to construct a CXCL16 humanized mouse model.

[0051] The 5' homology arm and 3' homology arm were obtained by PCR amplification using C57BL / 6 mouse genomic DNA or BAC library as templates, and the gene fragment of human CXCL16 was obtained by PCR amplification using the synthetic human CXCL16 gene fragment as template. The fragment was connected to the PBR322-MCS plasmid using the In-fusion kit to obtain the homologous recombination vector PBR322-CXCL16. After the vector was verified to be correct by restriction digestion and sequencing, it was used for subsequent fertilized egg microinjection.

[0052] Fertilized eggs of C57BL / 6 mice were taken, and the PBR322-CXCL16 recombinant vector, Cas9 mRNA and gRNA were mixed according to the method in the Mouse Embryo Operation Experiment Manual (3rd Edition) and microinjected into the fertilized eggs. After a short period of incubation in the incubator, the injected fertilized eggs were transplanted into the oviduct of the recipient mother mouse to obtain gene-modified mice F0 generation mice. After the F0 generation mice were born, the tails were cut and the genome was extracted. The 5' homologous arm and 3' homologous arm homologous recombination positive clones were PCR identified by long fragment PCR. The primer positions for PCR identification are shown in the figure below. Figure 3 The specific identification information of homologous recombination in F0 and F1 generation mice is shown below.

[0053] The conditions for identifying 5' arm homologous recombination are as follows: The primer sequence information is as follows: Primer name Sequence information (5'→3') P1 AGCTTCCTTGTTAAAGGTTTCACTG (SEQ ID NO: 11) P2 AAAACAAGTCAATAACCGCCTCTTT (SEQ ID NO: 12)

[0054] The PCR reaction system is as follows: PCR reaction composition Volume(µL) <![CDATA[ddH2O]]> 8.05 2xPCR Buffer 10 Primer P1 (20pmol / µL) 0.3 Primer P2 (20pmol / µL) 0.3 KOD-Multi&Epi-* 0.35 Genomic DNA 1 total 20

[0055] * KOD-Multi&Epi-(TOYOBO, Code No: KME-101) The PCR reaction procedure is as follows: step Temperature (℃) time Remark 1 94 3 min 2 98 20 sec 3 63 20 sec 4 68 4 min Repeat steps 2-4 for a total of 35 cycles 5 68 5 min 6 12 10 min

[0056] The conditions for identifying 3' arm homologous recombination are as follows: The primer sequence information is as follows: Primer name Sequence information (5'→3') P3 ATGCTGTCATCTCCTCTTCTACTTC (SEQ ID NO: 13) P4 TGGAACTGTCCAAGGAAAAGACTAA (SEQ ID NO: 14)

[0057] The PCR reaction system is as follows: PCR reaction composition Volume(µL) <![CDATA[ddH2O]]> 8.05 2xPCR Buffer 10 Primer P3 (20pmol / µL) 0.3 Primer P4 (20pmol / µL) 0.3 KOD-Multi&Epi-* 0.35 Genomic DNA 1 total 20

[0058] * KOD-Multi&Epi-(TOYOBO, Code No: KME-101) The PCR reaction procedure is as follows: step Temperature (℃) time Remark 1 94 3 min 2 98 20 sec 3 63 20 sec 4 68 4 min Repeat steps 2-4 for a total of 35 cycles 5 68 5 min 6 12 10 min

[0059] According to the design strategy and identification scheme, the 5' arm homologous recombination positive genome should amplify a 5.3 kb fragment, and the negative genome should amplify a 11.7 kb fragment; the 3' arm homologous recombination positive genome should amplify a 4.4 kb fragment, and the negative genome should amplify a 10.6 kb fragment. The identification electrophoresis results are as follows Figure 4 Middle A and Figure 4 As shown in B. After PCR identification and sequencing confirmation, a total of 2 positive mice were obtained, numbered: 4 and 6. F0 mice were mated with wild-type C57BL / 6 mice when they were adults to obtain F1 mice. After the F1 mice were born, their tails were cut and the genome was extracted. The same conditions as those for identifying homologous recombination in F0 mice were used to perform PCR identification on the 5' homologous arm and the 3' homologous arm, respectively, to confirm whether the obtained F1 mice were the offspring of the CXCL16 gene humanized mice with correct homologous recombination. The positive mice were F1 heterozygous mice. The PCR identification results are shown in Figure 4 Middle C and Figure 4 As shown in D, the positive mice are Nos. 6, 7, 9, 12, 15, and 18. F1 generation heterozygous mice were self-crossed to obtain CXCL16 humanized homozygous mice.

[0060] The above results show that this method can be used to efficiently construct a CXCL16 gene humanized mouse model that can be stably propagated.

[0061] Example 2 Verification of expression of human CXCL16 in a humanized mouse model 1) Verification of mRNA expression of human CXCL16 in humanized mouse models Humanized CXCL16 homozygous mice and a wild-type mouse of the same litter (6 weeks old) were selected to extract total lung RNA, which was reverse transcribed into cDNA using a reverse transcription kit. PCR was then performed using cDNA as a template to verify the expression level of human CXCL16 mRNA in humanized mice.

[0062] In this experiment, primers for detecting mouse Cxcl16 and human CXCL16 RNA were designed, and the positions are as follows: Figure 5 The positions of P5 / P6 and P7 / P8 primers are shown in Figure 1. The RNA detection results are shown in Figure 2. Figure 6 As shown. The primer sequences for detecting the expression of mouse CXCL16 RNA are: P5: 5'- TGTCTCTTGCGTTCTTCCT-3' (SEQ ID NO: 15), and P6: 5'- GAAAACTCTTCCCATGACCAG-3' (SEQ ID NO: 16), PCR product is 300 bp; The primer sequences for human CXCL16 RNA expression detection are: P7: 5'-AGAGCTTCCATCGGTGTC-3' (SEQ ID NO: 17), and P8: 5'-GGACGAGTGAGCTCTTTGT-3' (SEQ ID NO: 18), the PCR product size is 314 bp.

[0063] The PCR reaction system and reaction conditions of the two primer pairs P5 / P6 and P7 / P8 were the same, 20μL PCR system, reaction conditions: 94℃, 4min; (94℃, 15sec; 58℃, 15sec; 72℃, 45sec, 32 cycles); 72℃, 5min; 12℃ insulation.

[0064] The above results indicate that active human CXCL16 expression can be detected at the RNA level in CXCL16 humanized mice.

[0065] 2) Verification of protein expression of human CXCL16 in humanized mouse models In order to verify whether humanized CXCL16 protein is expressed after humanization, the applicant detected the expression of CXCL16 protein in the serum of wild-type mice and CXCL16 humanized homozygous mice by ELISA. The results were consistent with expectations ( Figure 7 ): Wild-type mice do not express human CXCL16 protein, while CXCL16 humanized homozygous mice express human CXCL16 protein.

[0066] The results indicate that human CXCL16 protein can be expressed in humanized CXCL16 mice, and this mouse model can be used to conduct related studies such as drug screening and verification at the preclinical animal level.

[0067] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for constructing a CXCL16 gene humanized animal model, characterized in that: Using gene editing technology, a homologous recombination vector is used to replace the nucleotide sequence shown in SEQ ID NO: 3 in the animal Cxcl16 gene with a human CXCL16 gene fragment; The homologous recombination vector comprises a 5' homology arm, a human CXCL16 gene fragment and a 3' homology arm arranged in sequence from the 5' end to the 3' end; Wherein, the human CXCL16 gene fragment is selected from at least one of the following groups: 1) a replacement region of the human CXCL16 gene having a nucleotide sequence as shown in SEQ ID NO: 1; 2) a replacement region of the human CXCL16 gene having a nucleotide sequence as shown in SEQ ID NO: 9; 3) a nucleotide fragment encoding the amino acid sequence shown in SEQ ID NO: 2; The nucleotide sequence of the 5' homology arm is shown in SEQ ID NO: 7; The nucleotide sequence of the 3' homology arm is shown in SEQ ID NO: 8; Wherein, gene editing is achieved using sgRNA, the sequence of the 5' target site targeted by the sgRNA is shown in SEQ ID NO: 19, and the sequence of the 3' target site targeted by the sgRNA is shown in SEQ ID NO:

20.

2. The method for constructing a CXCL16 gene humanized animal model according to claim 1, characterized in that: Injecting a mixture of homologous recombination vectors, sgRNA and Cas9 into non-human animal cells, transferring the non-human animal cells into a culture medium for culture, and then screening to obtain CXCL16 gene humanized animal cells; Wherein, the Cas9 includes Cas9 mRNA and / or Cas9 protein.

3. The method for constructing a CXCL16 gene humanized animal model according to claim 2, characterized in that: In the CXCL16 gene humanized animal cells, the expression of endogenous Cxcl16 gene in non-human animal cells is reduced or eliminated, while humanized CXCL16 protein is expressed and produced.

4. The method for constructing a CXCL16 gene humanized animal model according to claim 2, characterized in that: The following steps are also included: S1: transplanting the CXCL16 gene humanized animal cells, or embryos developed from the CXCL16 gene humanized animal cells, into a surrogate mother for development to obtain F0 generation animals; S2: Selecting animals with positive genotype identification as F0 positive animals; then hybridizing and self-pollinating the F0 positive animals, and self-pollinating the heterozygous animals to obtain homozygous animals, thereby establishing stable humanized CXCL16 gene-modified animals; S3: The humanized CXCL16 gene-modified animal described in S2 is subjected to detection of humanized CXCL16 expression in tissues. If humanized CXCL16 is expressed, the humanized CXCL16 gene-modified animal is used as a CXCL16 gene humanized animal model.

5. Application of the humanized animal model of CXCL16 gene obtained by the construction method according to any one of claims 1 to 4 in fields related to human CXCL16 gene or protein.

6. The use according to claim 5, characterized in that The application includes at least one of human CXCL16 gene function research, human CXCL16 antibody research, and drug construction and efficacy research targeting human CXCL16 target sites.

Citation Information

Patent Citations

  • Genetically sterile animals

    CN105473714A

  • Construction method and application of humanized CCR2 gene modified animal model

    CN111690689A

  • Construction method of humanized CD40 gene modified animal model and application thereof

    CN112725379A

  • Construction method and application of SIGLEC15 gene humanized animal model

    CN114134183A

  • Human cxcli6 antibodies and the use thereof

    US20240327509A1

Cited By

  • Construction method and application of C5AR1 gene humanized animal model

    CN119120576A